Get the Stockscreener App
18.79
2.39%
-0.46
After Hours:
18.68
-0.11
-0.59%
Urogen Pharma Ltd stock is traded at $18.79, with a volume of 886.22K.
It is down -2.39% in the last 24 hours and down -2.14% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$19.25
Open:
$19.1
24h Volume:
886.22K
Relative Volume:
0.42
Market Cap:
$869.30M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-5.1199
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-0.48%
1M Performance:
-2.14%
6M Performance:
+73.66%
1Y Performance:
+43.98%
1-Day Range:
$18.67
$19.20
1-Week Range:
$18.45
$21.71
52-Week Range:
$3.42
$21.71
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
18.79 | 884.11M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Urogen Pharma (NASDAQ:URGN) Stock Price Down 8% on Insider Selling - MarketBeat
Parkman Healthcare Partners LLC Has $4.35 Million Holdings in Urogen Pharma $URGN - MarketBeat
Adage Capital Partners GP L.L.C. Sells 1,651,086 Shares of Urogen Pharma $URGN - MarketBeat
Brokerages Set Urogen Pharma (NASDAQ:URGN) PT at $32.00 - MarketBeat
Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 Shares - MarketBeat
Urogen Pharma (NASDAQ:URGN) General Counsel Jason Drew Smith Sells 1,520 Shares - MarketBeat
Urogen Pharma (NASDAQ:URGN) Reaches New 12-Month HighShould You Buy? - MarketBeat
Urogen Pharma (NASDAQ:URGN) Shares Up 10.6%What's Next? - MarketBeat
UroGen Pharma’s chief medical officer Schoenberg sells $16k in shares - Investing.com India
Urogen Pharma (URGN) general counsel sells $29k in shares - Investing.com
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - simplywall.st
UroGen Pharma at H.C. Wainwright Conference: Zosduri’s Market Impact By Investing.com - Investing.com Australia
UroGen Pharma at H.C. Wainwright Conference: Zosduri’s Market Impact - Investing.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
UroGen Pharma (URGN) Awards Restricted Stock Units to New Employ - GuruFocus
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing R - GuruFocus
Urogen Pharma announces inducement grants under Nasdaq Listing Rule - MarketScreener
67,700 Shares: UroGen Pharma Expands Team with 40 New Hires to Drive Cancer Treatment Portfolio Growth - Stock Titan
How cyclical is UroGen Pharma Ltd.’s revenue streamQuarterly Performance Summary & Reliable Entry Point Alerts - beatles.ru
Can UroGen Pharma Ltd. stock outperform in a bear marketCEO Change & Stepwise Entry/Exit Trade Alerts - beatles.ru
RA Capital Management L.P. Takes $35.46 Million Position in Urogen Pharma $URGN - MarketBeat
Vestal Point Capital LP Has $23.81 Million Position in Urogen Pharma $URGN - MarketBeat
Can UroGen Pharma Ltd. keep up with sector leadersAnalyst Upgrade & Weekly Top Stock Performers List - خودرو بانک
Should I hold or sell UroGen Pharma Ltd. now2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - خودرو بانک
Will UroGen Pharma Ltd. stock go up in YEARJuly 2025 Chart Watch & Expert Approved Trade Ideas - خودرو بانک
92,957 Shares in Urogen Pharma $URGN Acquired by Nuveen LLC - MarketBeat
Can UroGen Pharma Ltd. disrupt its industryMarket Performance Recap & Reliable Trade Execution Plans - خودرو بانک
Institutional scanner results for UroGen Pharma Ltd.Trend Reversal & Risk Adjusted Buy/Sell Alerts - Newser
How to use Fibonacci retracement on UroGen Pharma Ltd.Quarterly Performance Summary & Precise Swing Trade Alerts - Newser
UroGen Pharma at Cantor Conference: Strategic Moves for Growth - Investing.com India
UroGen Pharma at Cantor Conference: Strategic Moves for Growth By Investing.com - Investing.com Australia
Should you avoid UroGen Pharma Ltd. stock right nowJuly 2025 Market Mood & Weekly Top Stock Performers List - خودرو بانک
How hedge fund analytics apply to UroGen Pharma Ltd. stockJuly 2025 Gainers & Free Reliable Trade Execution Plans - Newser
Published on: 2025-09-04 03:44:16 - Newser
Comparing UroGen Pharma Ltd. in custom built stock radarsTrade Risk Report & Smart Money Movement Alerts - Newser
Real time pattern detection on UroGen Pharma Ltd. stock2025 Valuation Update & Reliable Volume Spike Trade Alerts - Newser
Can momentum traders help lift UroGen Pharma Ltd.Earnings Beat & Technical Pattern Alert System - Newser
Will UroGen Pharma Ltd. benefit from macro trendsWeekly Earnings Recap & Low Volatility Stock Suggestions - Newser
How to escape a deep drawdown in UroGen Pharma Ltd.July 2025 Trends & Target Return Focused Stock Picks - Newser
Using data filters to optimize entry into UroGen Pharma Ltd.July 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
Will earnings trigger a reversal in UroGen Pharma Ltd.2025 Market Outlook & Verified Short-Term Trading Plans - Newser
UroGen Pharma Ltd. stock prediction for this week2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
What recovery options are there for UroGen Pharma Ltd.July 2025 Summary & Reliable Volume Spike Alerts - Newser
Will breakout in UroGen Pharma Ltd. lead to full recoveryMarket Risk Report & Real-Time Buy Signal Alerts - Newser
Visual trend scoring systems applied to UroGen Pharma Ltd.Portfolio Value Report & Safe Entry Momentum Tips - Newser
What is UroGen Pharma Ltd. s 5 year growth outlookMarket Risk Report & Technical Confirmation Alerts - خودرو بانک
Will UroGen Pharma Ltd. benefit from rate cutsJuly 2025 Chart Watch & Fast Gaining Stock Reports - خودرو بانک
Heatmap analysis for UroGen Pharma Ltd. and competitorsJuly 2025 Fed Impact & Technical Buy Zone Confirmations - Newser
Is UroGen Pharma Ltd. stock overvalued or fairly pricedQuarterly Portfolio Summary & Low Risk Entry Point Guides - خودرو بانک
Analysis Recap: Can UroGen Pharma Ltd. keep up with sector leadersJuly 2025 Retail & Safe Investment Capital Preservation Plans - خودرو بانک
Does UroGen Pharma Ltd. have declining or rising EPSQuarterly Investment Review & Verified Technical Trade Signals - خودرو بانک
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):